Abstract The EORTC Lung Cancer Cooperative group performed a randomised phase II
study in patients with small cell lung cancer comparing the standard cyclophosphamide …

VP-16 and cisplatin were used as first-line therapy in 31 patients with small-cell lung cancer
(SCLC) in whom chemotherapy regimens that contained doxorubicin (Adriamycin [Adria …

SFTER THE EARLY realization that locoregional treatment modalities contributed little to the
survival of patients suffering from small-cell lung cancer (SCLC), a disease with a …

To determine the efficacy and toxicity of irinotecan combined with carboplatin, we conducted
a phase II trial. Eligibility criteria were: chemotherapy-naïve, small-cell lung cancer (SCLC) …

Objective: This study was conducted in refractory or relapsed small-cell lung cancer to
determine activity and toxicity of the combination of cisplatin, ifosfamide, and irinotecan with …

Summary Background From 1980 to 1983 the Swiss Group for Clinical Cancer Research
(SAKK) performed a randomised phase HI trial in patients with small-cell lung cancer with …

Introduction Bevacizumab's role in the treatment of small cell lung cancer (SCLC) is
unknown. A multicenter phase II trial with bevacizumab plus chemotherapy was conducted …

One hundred and fourteen patients with small cell lung cancer received a combination of
etoposide 80 mg/m 2 IV days 1, 2, 3, 15, 16, 17, cisplatin 20 mg/m 2 IV days 1, 2, 3 and …

Chemotherapy is currently the main treatment for all stages of small-cell lung cancer. In
extensive disease, etoposide/cisplatin (Platinol) is standard treatment, and in limited …

7054 Background: We previously conducted a phase I trial of combination chemotherapy
with topotecan and amrubicin for SCLC and found acceptable toxicity profiles with a …